Loading chat...
MN HF4014
Bill
Status
Introduced
5/16/2016
Primary Sponsor
Nick Zerwas
Click for details
AI Summary
- Modifies Medical Assistance and EPSDT program coverage to allow investigational drugs, biological products, and devices for children under 21 years of age if three conditions are met.
- Requires the investigational treatment to be generally accepted by the professional medical community as an effective and proven treatment for the condition being treated.
- Requires the investigational treatment to not be novel, relatively unknown, or rarely used for the condition being prescribed.
- Requires the treating physician to have received an individual patient investigational new drug (IND) approval for treatment use from the United States Food and Drug Administration.
- Mandates that the commissioner give significant weight to the opinion of the patient's treating physician when determining whether EPSDT coverage must be provided for investigational treatments.
Legislative Description
Investigational drug, biological product, or device coverage provided under the early periodic screening, diagnosis, and treatment program.
Last Action
Introduction and first reading, referred to Health and Human Services Reform
5/16/2016
Committee Referrals
Health and Human Services Reform5/16/2016
Full Bill Text
No bill text available